Cantargia presents the interim report for Q2 2024 on August 28 at 3.00 p.m. https://lnkd.in/dG5M_Ufr
Cantargia AB
Forskning inom bioteknik
Lund, Skåne County 3 195 följare
A Swedish listed biotechnology company
Om oss
Cantargia develops antibody based therapies against the target IL1RAP. The two clinical programs are nadunolimab in phase II development for treatment of cancer, and CAN10 in phase I development for autoimmune/inflammatory diseases.
- Webbplats
-
http://www.cantargia.com
Extern länk för Cantargia AB
- Bransch
- Forskning inom bioteknik
- Företagsstorlek
- 11–50 anställda
- Huvudkontor
- Lund, Skåne County
- Typ
- Publikt aktiebolag
- Grundat
- 2010
Adresser
-
Primär
Scheelevägen 27
Lund, Skåne County 22363, SE
Anställda på Cantargia AB
Uppdateringar
-
Interview with CEO Göran Forsberg regarding new results in pancreatic cancer. https://lnkd.in/dxeGbEdk
Cantargia: Intervju med vd Göran Forsberg om ASCO GI och XBiotech
redeye.se
-
Cantargia presents Phase 2 clinical data in pancreatic cancer with nadunolimab at ESMO Gastrointestinal Cancer Congress 2024. https://lnkd.in/d5XbRPG6 #CANTA #CAN04 #IL1RAP #CANCER
Cantargia presents Phase 2 clinical data in pancreatic cancer with nadunolimab at ESMO Gastrointestinal Cancer Congress 2024
cantargia.com
-
We are currently searching for a Senior Scientist Bioprocess and CMC. Read more and apply below. #recruiting #Cantargia #CMC #jobopening https://lnkd.in/dAgQS2q6
Senior Scientist Bioprocess and CMC
apply.workspacerecruit.com
-
Cantargia söker en Financial Controller. Läs mer och sök tjänsten nedan. https://lnkd.in/dBUqqkZv
Financial Controller
apply.workspacerecruit.com
-
Cantargia strengthen management team with the appointment of Ton Berkien as Chief Business Office https://lnkd.in/dJTRmQSW #Cantargia #IL1RAP
Cantargia strengthen management team with the appointment of Ton Berkien as Chief Business Officer
cantargia.com
-
Cantargia ASCO presentation highlights positive clinical data on nadunolimab counteracting neuropathy. https://lnkd.in/d8wZt9Mp
-
-
Invitation to presentation of Cantargia’s interim report for Q1 2024 on May 21 at 3.00 p.m. CEST https://lnkd.in/d5erTw4E
Invitation to presentation of Cantargia’s interim report for Q1 2024 on May 21 at 3.00 p.m. CEST
cantargia.com
-
Upcoming events in May. Read more on our website. https://lnkd.in/eX8jdwnB
-
-
Cantargia publishes Annual Report for 2023. https://lnkd.in/dkF4YsVZ
Financial reports
cantargia.com
Liknande sidor
Finansiering
Senaste finansieringsrunda
Aktiekapital efter börsintroduktion24 732 395,00 US$